LifeScience Clinical & Diagnostic
Mr. Yaw Kong Yap has stepped down from his role as the chief financial officer and president of the Company due to reaching retirement age, effec...
October 03, 2022 | News
As Illuccix rolls out to positron emission tomography (PET) sites across the country, Mercy Radiology in Auckland became the first to administer ...
September 30, 2022 | News
Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, ...
September 28, 2022 | News
NMS-293 is a next generation, orally available, brain-penetrant PARP1 selective inhibitor NMS-293 is currently studied in Phase I as monotherapy for the...
September 27, 2022 | News
Proton therapy can be used to treat many of the most common types of cancer. All radiotherapy, including proton and high energy X-rays (photon), destroys c...
September 26, 2022 | News
Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumo...
September 21, 2022 | News
A NEW targeted therapy to treat a rare bile duct cancer called cholangiocarcinoma has been approved for use in Australia. PEMAZYRE® (pemigat...
September 16, 2022 | News
The award will fund the continued advancement of the company's proprietary PANDAA™ technology platform and its specific application to the univ...
September 13, 2022 | News
Respiratory tract infections are associated with high morbidity and mortality worldwide, and their symptoms may not point to a single diagnosis. In such ca...
September 07, 2022 | News
Vascette® is a unique, topical closure pad incorporating a proprietary, plant-derived hemostatic foam. The Vascette® patent-pending technology supp...
August 25, 2022 | News
Sonde Health, a leading enterprise vocal biomarker company, has signed a multi-year agreement with Koye Pharmaceuticals, a specialty pharma organizati...
August 25, 2022 | News
Caption: 3D CMOS chip for connecting electroactive tissues and organoids to software.To download image, please click here. ...
August 24, 2022 | News
lacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line...
August 21, 2022 | News
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Accelerate Diagnostics, Inc. (NASDAQ:...
August 15, 2022 | News
Most Read
Bio Jobs
News